Panelists discuss how the SUNLIGHT trial and real-world evidence support FTD/TPI with or without bevacizumab as an effective third-line option in metastatic colorectal cancer. Panelists examine the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results